Athersys Inc (ATHXQ)

[goupupup]

Novel delivery of cellular therapy to reduce ischaemia reperfusion injury in kidney transplantation:
The MAPC cells used in this study were obtained in collaboration with Athersys Inc, Ohio, and were provided as pre-dosed cryovial aliquots of 25x106 cells. This is the first reported series of cell therapy successfully delivered directly to human donor kidneys in an isolated ex vivo perfusion platform. Kidneys treated with MAPC cells during NMP demonstrate improvement in clinically relevant functional parameters and a reduction in injury and pro-inflammatory biomarkers. This is a paradigm shift, providing an exciting opportunity to directly treat organs prior to transplantation to minimise ischaemia reperfusion injury. A future clinical trial evaluating this modality of delivery could result in the transplantation of otherwise discarded organs, thereby reducing the transplant waiting list and offering hope to patients with renal failure.
https://www.medrxiv.org/content/10.1101/19005546v1.full.pdf

Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19:
Anti-inflammatory therapies for patients with ARDS have been developed using stem cells offering a great promise for managing ARDS. MSCs related cell-therapies demonstrate high efficacy in preclinical data allowing their clinical usage. The MCC950 molecule could affect the binding of SARS-CoV-2 to cells and inhibit the amplification of the intracellular virus, and also the ComC inhibitors that assist in modulating the activity of the innate immune system [93]. Another possible inhibition therapy against SARS-CoV-2 is the use of ACE2 + MSC-derived small extracellular vesicles (sEVs) overexpressed, as suggested by Inal.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442550/